Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Best Veggie lover Dinner: What's Your Plant-Based Pick? - 2Inconceivable Spots To Stargaze All over The Planet
- 3Oil Tanker Carrying Iraqi Cargo Seen Transiting Strait of Hormuz
- 4Mechanical Sidekick d: A Survey of \Elements and Execution d\ Cell phone
- 5Opening Your True capacity: 12 Techniques for Personal growth
- 10 Energizing Vocations in the Innovation Business
- UK to hold fresh pork, other affected Spanish products at border amid African swine fever outbreak
- 5 Fundamental Ways to employ a Criminal Legal counselor
- Comet Lemmon and Milky Way spotted over Hawaii | Space photo of the day for Dec. 12, 2025
- Best Getaway destination: Ocean side, Mountain, or City
- The most effective method to Arrange a Higher Medical caretaker Pay During Your Next New employee screening
- 7 Countries Where Newcomers Feel Most Welcome, and 3 Where They Often Don’t
- Lebanese Shi’a party Amal competing, coordinating with Hezbollah, experts tell ‘Post’
- Takeaways from AP’s report on potential impacts of Alaska’s proposed Ambler Access Road
